Shivda Pandey

Published on 9/10/2025

Ruberg FL, Teruya S, Helmke S, Smiley DA, Fine D, Kurian D, Raiszadeh F, Prokaeva T, Spencer B, Wong S, Pandey S, Blaner WS, DeLuca A, Johnson LL, Kinkhabwala MP, Leb J, Mintz A, LaValley MP, Einstein AJ, Cohn E, Gallegos C, Murtagh G, Kelly JW, Miller EJ, Maurer MS. Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. JAMA Cardiol. 2025 Sep 10. PMID: 40928765.

Published on 9/1/2025

Pandey S. The case for serial quantitative cardiac amyloid radionuclide imaging - will nuclear cardiology continue to transform care in transthyretin cardiac amyloidosis? J Nucl Cardiol. 2025 Sep; 51:102446. PMID: 40973356.

Published on 9/12/2024

Hage FG, Bourque JM, Pandey S, Shah NR, Soman P, Abbott BG, Abidov A, Aggarwal NR, AlJaroudi W, Bhambhvani PG, Bokhari S, Dorbala S, Doukky R, Duran JM, Einstein AJ, Gallagher D, Hendel RC, Jaber W, Kattan CG, Malhotra S, Masri A, Miller EJ, Murthy VL, Sperry BW. American Society of Nuclear Cardiology quality metrics for cardiac amyloid radionuclide imaging. J Nucl Cardiol. 2024 Oct; 40:102041. PMID: 40590833.

Published on 12/1/2023

Chan N, Einstein AJ, Griffin JM, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson LL, Kinkhabwala MP, Leb JS, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith SE, Winburn M, Smiley D, Miller EJ, Ruberg FL, Maurer MS. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. J Nucl Cardiol. 2023 Dec; 30(6):2531-2539. PMID: 38245059.

Published on 6/13/2023

Chan N, Einstein AJ, Griffin JM, Rosenblum H, Teruya S, Cuomo M, De Los Santos J, DeLuca A, Johnson LL, Kinkhabwala MP, Leb JS, Mintz A, Fine D, Helmke S, Muralidhar V, Pandey S, Sabogal N, Saith SE, Winburn M, Smiley D, Miller EJ, Ruberg FL, Maurer MS. Prevalence and significance of extracardiac uptake on pyrophosphate imaging in the SCAN-MP study: the first 379 cases. J Nucl Cardiol. 2023 Dec; 30(6):2531-2539. PMID: 37311914.

Published on 4/17/2023

Ruberg FL, Blaner WS, Chiuzan C, Connors LH, Einstein AJ, Fine D, Helmke S, Kurian D, Pandey S, Raiszadeh F, Rodriguez C, Sabogal N, Teruya S, Winburn M, Chung WK, Cohn E, Miller EJ, Kelly JW, Maurer MS. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc. 2023 Apr 18; 12(8):e028534. PMID: 37066788.

Published on 2/23/2023

Pandey S, Teruya S, Rodriguez C, Deluca A, Kinkhabwala M, Johnson LL, Fine D, Sabogal N, Winburn M, Castillo M, Bhatia K, Malkovskaya R, Raiszadeh F, Kurian D, Miller EJ, Einstein AJ, Maurer MS, Ruberg FL. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc99m pyrophosphate (PYP) imaging for diagnosis of transthyretin (ATTR) cardiac amyloidosis: the SCAN-MP study. J Nucl Cardiol. 2023 Aug; 30(4):1414-1419. PMID: 36823486.

Published on 12/10/2021

Pandey S. Quantitative SPECT in PYP imaging: Ready for prime time or too early to tell? J Nucl Cardiol. 2022 Oct; 29(5):2691-2693. PMID: 34893962.

Published on 5/19/2021

Poterucha TJ, Elias P, Ruberg FL, DeLuca A, Kinkhabwala M, Johnson LL, Griffin JM, Pandey S, Einstein AJ, Maurer MS. False Positive 99mTc-Pyrophosphate Scanning Leading to Inappropriate Tafamidis Prescriptions. JACC Cardiovasc Imaging. 2021 10; 14(10):2042-2044. PMID: 34023264.

Published on 7/27/2018

Pandey S, Siddiqi OK. Tc-99m pyrophosphate imaging for transthyretin cardiac amyloidosis: Importance of estimation of cancer risk with the modality. J Nucl Cardiol. 2020 02; 27(1):225-227. PMID: 30054791.